Breaking News Instant updates and real-time market news.

Omnicell sees FY18 non-GAAP EPS $2.00-$2.05, consensus $

Sees FY18 non-GAAP revenue $787M-$793M, consensus $791.36M.

25

Oct

27

Nov

OMCLOmnicell

$61.38

0.58 (0.95%)

07/27/18

07/27/18UPGRADETarget $65Buy

Omnicell upgraded to Buy on improved execution at Craig-Hallum

As previously reported, Craig-Hallum analyst Matt Hewitt upgraded Omnicell to Buy from Hold, noting that process changes the company put in place to "right the ship" appear to have had the desired effect as the company has now successfully executed through the first half of 2018. Also, the "highly anticipated" launches of IVX Workflow/IVX Cloud and XR2 Automated Central Pharmacy were both commercially launched in June, with the XR2 launch being ahead of schedule, said Hewitt. He raised his price target on Omnicell shares to $65 from $50.

09/17/18

CHLM

09/17/18NO CHANGETarget $80CHLMBuy

Omnicell price target raised to $80 from $65 at Craig-Hallum

Craig-Hallum analyst Matt Hewitt reiterated a Buy rating on Omnicell and raised his price target to $80 from $65 following the results of a recent industry survey. In a research note to investors, Hewitt says he was encouraged to see that Omnicell was the leading vendor of automated dispensing cabinets amongst customers surveyed in Pharmacy Purchasing & Products' annual State of Pharmacy Automation survey, with 49% using its cabinets vs. 37% last year, demonstrating that the launch of the XT is helping the company continue to take share from competitors. Hewitt notes that the survey indicates Omnicell is at or near the top of the list for many of its product categories where hospitals are considering buying over the next few years. Given the strong trends across multiple product categories for Omnicell, Hewitt sees the potential for accelerating growth in both bookings and product revenue, especially as newer products like the XR2 and IVX gain meaningful traction.

Benchmark analyst Bill Sutherland said Omnicell appears to be entering a multi-year period of above-average growth and expanding margins following the recent launch of several products. He expects bookings momentum to continue to build and thinks margin growth could exceed current 2019-2020 consensus, Sutherland added. He raised his price target on Omnicell shares to $79 from $66 and keeps a Buy rating on the stock.

10/22/18

OPCO

10/22/18NO CHANGETarget $71OPCOOutperform

Omnicell price target raised to $71 from $59 at Oppenheimer

Oppenheimer analyst Mohan Naidu raised his price target for Omnicell (OMCL) to $71 from $59 as his channel checks ahead of Q3 show consistent market share gains in cabinets and steady XT feedback from customers. The analyst expects an in-line Q3, but the timing of XR2 release and implementation could provide upside to Q4. While the core business continues to execute well, investors' attention is slowly shifting toward the MedAdherence segment after Amazon's (AMZN) acquisition of PillPack, but Naidu cautions that numbers upside could be limited from that segment in the near-term. He reiterates an Outperform rating on Omnicell shares.

TODAY'S FREE FLY STORIES

According to a regulatory filing, Ryan Graves informed Uber Technologies of his intention to resign as a member of the company's board of directors, effective as of May 27, 2019, including any committees of the board of directors on which he serves. Graves' resignation was not the result of any disagreement between Graves and the company, its management, board of directors or any committee thereof, or with respect to any matter relating to the company's operations, policies or practices, according to the filing.

U.S. Energy announced that on May 21, Nasdaq notified the company that as a result of not having received its Quarterly Report on Form 10-Q for the period ended March 31. 2019, and because the company is delinquent in filing its Form 10-K for the year ended December 31, 2018, the company does not comply with the requirements of Nasdaq Listing Rule 5250(c)(1) for continued listing on the Exchange. This notification has no effect on the listing of the company's common stock at this time. However, pursuant to the notice, the company was required to submit a plan by May 23, 2019 to comply with the Exchange's requirements for continued listing.

Apple is being sued by customers alleging that the U.S. tech giant is unlawfully disclosing and selling information about users' iTunes purchases as well as their personal data, Bloomberg's Robert Burnson reports. The customers claim that such alleged practices are contrary to Apple's promise in advertising that "What happens on your iPhone stays on your iPhone," Burnson notes. Reference Link

SuperCom received a notification from Nasdaq for not having timely filed its Annual Report on Form 20-F for the year ended December 31, 2018, as previously disclosed by the company on May 16, 2019. The company does not comply with the Nasdaq Listing Rule 5250(c)(1). This notice from Nasdaq has no effect currently on the listing of the company's common stock on the Nasdaq Capital Market.

U.S. Energy announced that Nasdaq notified the company that as a result of not having received the company's quarterly report on Form 10-Q for the period ended March 31 and because the company is delinquent in filing its Form 10-K for the year ended December 31, 2018, the company does not comply with the requirements of Nasdaq Listing Rule 5250 for continued listing on the exchange. This notification has no effect on the listing of the company's common stock at this time. However, pursuant to the notice, the company was required to submit a plan by May 23 to comply with the exchange's requirements for continued listing. The company has submitted the plan to the exchange. If the exchange accepts the company's Plan, the exchange may grant an exception of up to 180 calendar days from the Form 10-K's due date, or until October 14 to regain compliance. The company continues to work toward the filing of the Form 10-Q and the Form 10-K with the SEC as soon as practicable.

Qiagen (QGEN) announced the launch of its therascreen PIK3CA RGQ PCR Kit after it received U.S. regulatory approval as a companion diagnostic to aid in identifying breast cancer patients eligible for treatment with PIQRAY, a newly approved therapy developed and marketed by Novartis (NVS). The therascreen PIK3CA Kit is the first companion diagnostic assay to obtain premarket approval from the FDA for use in any cancer indication for detection of activating mutations in the PIK3CA gene. It is also the first FDA approved assay for guiding treatment decisions in breast cancer using plasma specimens as a liquid biopsy.

Brazil's ANAC said it has suspended all flights and operations of Avianca Brasil in the South American nation as a precuartionary measure, Reuters reports. The move follows Avianca's filing for bankruptcy in late 2018, the report says. "All the flights are suspended until the company proves it has the capacity to maintain operations safely," ANAC said. Reference Link

Apple has bought Tueo Health, a start-up that was making a system to help parents monitor asthma symptoms in sleeping kids, CNBC's Christina Farr and Steve Kovach report, citing a person familiar with the deal. It is not clear how much the U.S. tech giant paid for the start-up, the authors note. Reference Link

A review of Boeing's grounded 737 MAX aircraft has expanded to include emergency procedures used by pilots on earlier models of the plane, further delaying its return to service, the Wall Street Journal's Andy Pasztor reports, citing U.S. government officials. The FAA hasn't questioned the safety of older aircraft currently in service, but the broadened review will play a major role in adding months to the time expected to get the grounded fleet of 737 MAX jets back in the skies, Pasztor notes. As part of the FAA's safety analysis of a proposed software fix for the fleet, the agency is also weighing changes to how pilots of the entire 737 family are trained to respond when the flight-control computer or other systems suddenly push the jet's nose down, the author says. Reference Link

The CBOE Volatility Index (VIX), the SPX option derived measure of implied volatility, fell 1.07 today to close at 15.85, while the underlying SPX index gained 3.82 to close at $2826.06, a 0.14% increase. 274,267 VIX option contracts traded, 38.73% of the typical daily volume for the product. Calls made up 74.0% of the volume.

Volume was average for this time of day. Breadth was mixed with issues and volume bullish while new highs to new lows were bearish (negative divergence). Advancing Issues: 2009 / Declining Issues: 1048 -- for a ratio of 1.9 to 1. Advancing Volume: 915,942,000 / Declining Volume: 681,710,000 -- for a ratio of 1.3 to 1. New 52-Week Highs: 57 / New 52-Week Lows: 114.

Volume was below average for this time of day. Breadth was bullish across the board. Advancing Issues: 1963 / Declining Issues: 956 -- for a ratio of 2.1 to 1. Advancing Volume: 1,549,354,000 / Declining Volume: 986,891,000 -- for a ratio of 1.6 to 1. New 52-Week Highs: 138 / New 52-Week Lows: 89.

Regional Health Properties, Inc. announcement concerning the company's noncompliance with the continued listing standards of NYSE American LLC. On May 21, 2019, the company received an official notice of noncompliance from the Exchange stating that the company is not in compliance with the Exchange's continued listing standards under the timely filing criteria outlined in Section 1007 of the Exchange's company Guide because the company failed to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2019, which was due to be filed with the Securities and Exchange Commission no later than May 20, 2019. For the reasons previously disclosed in its Form 12b-25 filed with the Securities and Exchange Commission on May 16, 2019, the company has not timely filed the Delayed Form 10-Q because additional time is needed to finalize the Delayed Form 10-Q and furnish the XBRL Interactive Data File exhibits required by Item 601b101 of Regulation S-K. The company is actively working to complete the Delayed Form 10-Q and intends to file the Delayed Form 10-Q under the Securities Exchange Act of 1934, as amended, within the next thirty days. As a result of the foregoing, the company has become subject to the procedures and requirements of Section 1007 of the Company Guide. During the six-month period from the date of the Filing Delinquency, the Exchange will monitor the company and the status of the Delayed Form 10-Q and any subsequent reports until the Filing Delinquency is cured. If the company fails to cure the Filing Delinquency within the Initial Cure Period, the Exchange may, in its sole discretion, allow the company's securities to be traded for up to an additional six-month period, depending on the company's specific circumstances. If the Exchange determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set forth in Section 1010 of the Company Guide.